TY - JOUR T1 - Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation JF - Journal of Clinical Pathology JO - J Clin Pathol SP - 687 LP - 692 DO - 10.1136/jclinpath-2012-200786 VL - 65 IS - 8 AU - Ching-Yih Lin AU - Yu-Feng Tian AU - Li-Ching Wu AU - Li-Tzong Chen AU - Li-Ching Lin AU - Chung-Hsi Hsing AU - Sung-Wei Lee AU - Ming-Jen Sheu AU - Hao-Hsien Lee AU - Yu-Hui Wang AU - Yow-Ling Shiue AU - Wen-Ren Wu AU - Hsuan-Ying Huang AU - Han-Ping Hsu AU - Chien-Feng Li AU - Shang-Hung Chen Y1 - 2012/08/01 UR - http://jcp.bmj.com/content/65/8/687.abstract N2 - Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT. Methods Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival. Results Present in 82 cases (47.7%), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced post-treatment tumour status (T3, T4, p<0.001) and inferior tumour regression grade (p=0.028). Of note, high-expression of Rsf-1 emerged as an adverse prognosticator for diseases-specific survival (p=0.0092) and significantly predicted worse MeFS (p=0.0006). Moreover, high-expression of Rsf-1 also remained prognostic independent for worse MeFS (HR 2.834; p=0.0214). Conclusions High-expression of Rsf-1 is associated with poor therapeutic response and adverse outcome in rectal cancer patients treated with neoadjuvant CRT, which confers tumour aggressiveness and therapeutic resistance through chromatin remodelling and represents a potential prognostic biomarker in rectal cancer. ER -